- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
75 result(s) found for: Radionuclide imaging.
Displaying page 1 of 4.
EudraCT Number: 2015-001211-13 | Sponsor Protocol Number: PRODROMALAD | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: IMAGING OF NEUROINFLAMMATION AND NEURODEGENERATION IN ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: mild cognitive impairment and familiar Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003669-24 | Sponsor Protocol Number: NET-2011-02346784 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Amyloid PET imaging study for the diagnosis of Alzheimer's disease in the preclinical/predementia phase | |||||||||||||
Medical condition: memory complaint, mild cognitive impairment, Alzheimer's Disease in predrmentia/prodromal disease phases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004244-35 | Sponsor Protocol Number: 1/25-03-2014 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:IRCCS Ospedale San Raffaele | |||||||||||||
Full Title: AMYLOID LOAD IN PRODROMAL AD WITH LIMBIC-PREDOMINANT PHENOTYPE PRINCIPAL INVESTIGATOR - STUDIO DEL CARICO DI AMILOIDE IN AD PRODROMICO CON FENOTIPO LIMBICO | |||||||||||||
Medical condition: mild cognitive impairment, Alzheimer's disease prodromal | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023120-24 | Sponsor Protocol Number: Nitro1 | Start Date*: 2011-10-18 | |||||||||||
Sponsor Name:MAASTRO clinic | |||||||||||||
Full Title: Nitroglycerin's effect on perfusion and hypoxia in human non small cell lung cancer: proof of principle, a phase II trial | |||||||||||||
Medical condition: non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005389-31 | Sponsor Protocol Number: FBB-HUG-2014 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:HôPITAUX UNIVERSITAIRES DE GENèVE | |||||||||||||
Full Title: Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study. | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004415-24 | Sponsor Protocol Number: 09/2011MolecularImaging | Start Date*: 2012-01-16 | |||||||||||
Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO | |||||||||||||
Full Title: Molecular imaging for the early diagnosis and monitoring of Alzheimer’s disease in old individuals with cognitive disturbances: an ADNI-compatible prospective study | |||||||||||||
Medical condition: Mild Congitive Impairment (MCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004328-40 | Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO | |||||||||||||
Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES | |||||||||||||
Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006810-35 | Sponsor Protocol Number: Glioma_Theranostics | Start Date*: 2022-11-02 |
Sponsor Name:Norwegian University of Science and Technology | ||
Full Title: 68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma | ||
Medical condition: Patients with confirmed recurrent grade 3 and grade 4 glioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003023-38 | Sponsor Protocol Number: CHUBX2017/47 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in pa... | |||||||||||||
Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001897-13 | Sponsor Protocol Number: ITM-LET-01 | Start Date*: 2017-08-22 | |||||||||||
Sponsor Name:ITM Solucin GmbH | |||||||||||||
Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar... | |||||||||||||
Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002093-40 | Sponsor Protocol Number: 104902 | Start Date*: 2017-08-30 |
Sponsor Name:Radboudumc | ||
Full Title: 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma | ||
Medical condition: Patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma or salivary duct carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013226-17 | Sponsor Protocol Number: AustrNHMRVID436677 | Start Date*: 2009-09-29 |
Sponsor Name:Plymouth Hospitals NHS Trust | ||
Full Title: The ENIGMA-II Trial. Nitrous oxide anaesthesia and cardiac morbidity after major surgery: a randomised controlled trial | ||
Medical condition: The study investigates standard anaesthesia for surgery. There is no single specific 'disease' rather there is a population of patients requiring anaesthesia to permit surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002773-21 | Sponsor Protocol Number: 89Zr-TLX250-003 | Start Date*: 2019-04-10 |
Sponsor Name:TELIX International Pty Ltd | ||
Full Title: A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal ce... | ||
Medical condition: Patients with an indeterminate renal mass (IRM) detected on contrast-enhanced abdominal MR imaging or equivalent standard of care imaging, clinically suspicious for renal cell carcinoma and schedul... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2008-007965-22 | Sponsor Protocol Number: IWT-TBM 0707181 | Start Date*: 2009-06-04 |
Sponsor Name:Nuclear Medicine UZ Gasthuisberg [...] | ||
Full Title: Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy | ||
Medical condition: Patients with a histological proven neuroendocrine tumour, without other curative options. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003268-11 | Sponsor Protocol Number: IEO676 | Start Date*: 2019-02-20 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC in patients with somatostatin receptor positive tumors (neuroendocrine tumors) | |||||||||||||
Medical condition: Neuroendocrine tumors in progression of disease and not suitable to additional treatments, positive to SSTR | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002196-34 | Sponsor Protocol Number: Neo.Lu.Pa.NET | Start Date*: 2019-11-07 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET) | |||||||||||||
Medical condition: Resectable pancreatic neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002686-30 | Sponsor Protocol Number: CEP-AZ-SH-02 | Start Date*: 2009-04-15 | |||||||||||
Sponsor Name:Christie Hospital NHS Foundation Trust | |||||||||||||
Full Title: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004313-13 | Sponsor Protocol Number: 20121001 | Start Date*: 2013-01-22 | |||||||||||
Sponsor Name:Skåne University Hospital, Dept of Oncology | |||||||||||||
Full Title: A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. | |||||||||||||
Medical condition: Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard Octreoscan | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001464-19 | Sponsor Protocol Number: GE-122-020 | Start Date*: 2016-02-11 | ||||||||||||||||
Sponsor Name:GE Healthcare Ltd. and its affiliates | ||||||||||||||||||
Full Title: AdreView™ Myocardial Imaging for Risk Evaluation – A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35% ADMIRE-ICD | ||||||||||||||||||
Medical condition: Heart failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005517-20 | Sponsor Protocol Number: IRST 100 01 | Start Date*: 2008-01-10 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||
Full Title: Receptor radionuclide therapy with [177Lu- DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. | |||||||||||||
Medical condition: cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
